Company news

Share this article:
Amylin has announced a corporate restructuring that will result in a reduction of workforces by 25%, or 340 employees. “Sales revenues have not met the expectations we had when we scaled up our organization,” said Daniel Bradbury, president and CEO at Amylin, in a statement.
 
A Pfizer manufacturing plant in Indiana has been put up for sale. The plant most recently manufactured Exubera, an inhaled insulin therapy, which didn't catch on with patients.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

AstraZeneca takes on pediatricians

The American Academy of Pediatricians says an AstraZeneca drug for preemies should be used less often, and the drugmaker is fighting back with an ad campaign that says the new guidelines put too many at risk.

UK generic use soared in 2013

Generics made up almost 75% of prescriptions in the United Kingdom last year.

GSK refutes consumer spin-off rumor

The company refutes a Financial Times rumor that one was happening soonish.